Clinical Trials
Toripalimab consolidation after chemoradiotherapy in limited-stage small cell lung cancer: a phase II, randomized controlled study (GASTO-1052A)
Zhang et alJournal for ImmunoTherapy of Cancer

In the phase II randomized controlled GASTO-1052A trial, consolidation therapy with the PD-1 inhibitor toripalimab demonstrated survival benefits and an acceptable safety profile in patients with limited-stage small cell lung cancer (LS-SCLC) following definitive concurrent chemoradiotherapy (CCRT).
The study enrolled 98 patients who completed CCRT between June 30, 2020, and May 31, 2024, randomizing them 1:1 to either toripalimab consolidation (240 mg every 3 weeks for up to 6 months; n=49) or observation (n=49). Randomization was stratified by disease stage (stage I/II vs stage III) and receipt of prophylactic cranial irradiation (PCI; yes vs no). The primary endpoint was progression-free survival (PFS), with secondary endpoints evaluating overall survival (OS), objective response rate (ORR), and adverse events. The trial was prematurely terminated on May 31, 2024.
Efficacy analysis showed marked improvements with toripalimab consolidation over observation. Median PFS was not reached in the toripalimab arm compared with 14.1 months (95% CI, 2.8–25.4) in the observation arm (HR, 0.55; 95% CI, 0.31–0.96). Similarly, median OS was not reached in the toripalimab cohort versus 30.3 months (95% CI, 20.4–40.2) with observation (HR, 0.39; 95% CI, 0.19–0.80). Objective responses were documented in 60.9% (14 of 23) of patients in the toripalimab group versus 37.5% (9 of 24) in the observation group. Subgroup analyses consistently favored toripalimab across all evaluated variables, including age, sex, ECOG performance status, smoking history, disease stage, CCRT response, and PCI administration.
Treatment-related toxicities were generally mild. Study drug discontinuation due to adverse events occurred in 12.5% (6 of 48) of patients receiving toripalimab. Severe pulmonary toxicity was limited: grade 3 pneumonitis or radiation pneumonitis occurred in 4.2% (2 patients) in the toripalimab arm compared with 2.0% (1 patient) in the observation arm. No grade 4 or 5 adverse events were reported in either cohort. While these findings highlight toripalimab consolidation as a promising post-CCRT strategy in LS-SCLC, the authors noted that larger randomized trials are warranted for definitive confirmation.
Key Takeaways
- Toripalimab consolidation significantly reduced the risk of disease progression (HR, 0.55; 95% CI, 0.31–0.96; median PFS not reached vs 14.1 months) and death (HR, 0.39; 95% CI, 0.19–0.80; median OS not reached vs 30.3 months) compared with observation after chemoradiotherapy.
- Objective response rates were 60.9% (14/23) in the toripalimab consolidation group compared with 37.5% (9/24) in the observation group.
- Grade 3 pneumonitis or radiation pneumonitis occurred in 4.2% of patients receiving toripalimab versus 2.0% in the observation arm, with adverse events prompting discontinuation in 12.5% of toripalimab-treated patients and no grade 4 or 5 events observed in either group.
Read the original sourceJournal for ImmunoTherapy of Cancer
